CD3
36 programs · 35 companies
Programs
36
Companies
35
Active Trials
22
Targeting CD3
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| SNY-4496 | Sanofi | Phase 2/3 | Endometrial CaCSU | |
| NVO-9630 | Novo Nordisk | Phase 2 | DMDFSGS | |
| Miriglumide | Alnylam | Phase 3 | Pancreatic CaCervical Ca | |
| Talatuximab | Samsung Biologics | Preclinical | Bladder CaGA | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | Prostate CaMeso | |
| SGM-7896 | Sangamo | Preclinical | FTDEoE | |
| CSL-8153 | CSL Limited | Approved | Wet AMDSLE | |
| Fixarapivir | Sun Pharma | Preclinical | WilmsCKD | |
| Teraratamab | PharmaEssentia | Preclinical | Rett | |
| Tirabrutinib | Bausch Health | Approved | PsoriasisObesity | |
| INO-9184 | Inovio | Phase 2/3 | Endometrial Ca | |
| Kematenlimab | Spyre Ther | Phase 2/3 | MDSIgAN | |
| MRK-3812 | Marker Therapeutics | Phase 3 | WMPSP | |
| Adagrazasiran | Reata Pharma (Biogen) | Approved | CLLPsoriasis | |
| Capisotorasib | Reata Pharma (Biogen) | Phase 1 | CKDMDS | |
| BLR-1526 | BioLineRx | Preclinical | Gastric Ca | |
| ARE-3396 | Arena (Pfizer) | Phase 3 | PsA | |
| Elrazumab | Allergan (AbbVie) | NDA/BLA | CMLPancreatic Ca | |
| Lisosertib | Sino Biopharma | Phase 1 | MSMeso | |
| 208-4501 | PharmAbcine | Phase 2/3 | Schizophrenia | |
| Rilunaritide | Affinia | Preclinical | HNSCCSCD | |
| NTR-7891 | Natera | Phase 1/2 | NASH | |
| GNL-2086 | Genelux | Preclinical | ThymomaGastric Ca | |
| Motainavolisib | PsiOxus (now Akeso) | Phase 1 | SLE | |
| RED-3997 | Redx Pharma | NDA/BLA | CF | |
| Lisolemzoparlimab | Novocure | Preclinical | Heart FailurePBC | |
| RLF-2389 | Relief Therapeutics | Approved | Ovarian CaAtopic Derm | |
| BAY-6963 | Bayer AG | Preclinical | Pancreatic CaPBC | |
| 416-6807 | Orient Pharma | Phase 2 | RAMDS | |
| INS-127 | Insud Pharma | Phase 2/3 | CSUPancreatic Ca | |
| AMO-4131 | Amoun Pharma | NDA/BLA | MyelofibrosisDravet | |
| Tixacilimab | Aspen Global | Phase 2/3 | RSVGA | |
| Riboosocimab | Dermavant Sciences | Phase 2 | Atopic DermCholangiocarcinoma | |
| PAH-7465 | Phibro Animal Health | Phase 2 | FSGSMS | |
| NEO-8617 | Neogen | Phase 1/2 | ADPKD | |
| ABU-7780 | Arbutus Biopharma | Phase 2/3 | CSUACC |